Novel oral anti-influenza prodrug candidate AV5075S.

OBJECTIVES Development of a novel drug candidate with improved activity against influenza virus neuraminidase (NA) compared with currently available therapeutics. METHODS Synthesized compounds were evaluated in vitro and in vivo. Three-dimensional molecular docking was successfully applied to classify compounds within the series by inhibitory potency. Stability was investigated in blood samples and in animal models. A pharmacokinetic study was performed in dogs and rats using peroral and intravenous administration. RESULTS A novel highly potent drug candidate [(3R,4R,5S)-4-(2,2-difluoroacetylamino)-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; AV5027] and its prodrug ethyl ester (AV5075S) were synthesized and tested. AV5027 and AV5075S exhibit picomolar activity against influenza virus NA. AV5075S inhibited NA in a model of pneumonia using mouse-adapted A/Aichi/2/68 (H3N2) virus significantly more strongly than oseltamivir phosphate. A general metabolic pathway was constructed for the parent compound based on experimental results and theoretical analyses. CONCLUSIONS AV5075S can be reasonably regarded as a novel 'next in class' oral drug candidate for the treatment of influenza.

[1]  Y. Ivanenkov,et al.  A novel influenza virus neuraminidase inhibitor AV5027. , 2013, Antiviral research.

[2]  Jinn-Moon Yang,et al.  Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities. , 2013, Organic & biomolecular chemistry.

[3]  T. Rungrotmongkol,et al.  Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1. , 2012, Journal of molecular graphics & modelling.

[4]  Ravi P. Shah,et al.  ICH guidance in practice: degradation behaviour of oseltamivir phosphate under stress conditions. , 2012, Journal of pharmaceutical and biomedical analysis.

[5]  George F. Gao,et al.  Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition , 2011, PLoS pathogens.

[6]  M. Yamashita,et al.  Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza , 2010, Antiviral chemistry & chemotherapy.

[7]  Ming-Rong Zhang,et al.  Radiosyntheses of two positron emission tomography probes: [11C]Oseltamivir and its active metabolite [11C]Ro 64-0802. , 2008, Bioorganic & medicinal chemistry letters.

[8]  Yasuyoshi Watanabe,et al.  A method for the synthesis of an oseltamivir PET tracer. , 2008, Bioorganic & medicinal chemistry letters.

[9]  K. Albert,et al.  Chemical stability of oseltamivir in oral solutions. , 2007, Die Pharmazie.

[10]  L. Di,et al.  Development and application of high throughput plasma stability assay for drug discovery. , 2005, International journal of pharmaceutics.

[11]  R Abagyan,et al.  High-throughput docking for lead generation. , 2001, Current opinion in chemical biology.

[12]  R. Webster,et al.  The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. , 2000, Antiviral research.

[13]  W. Lew,et al.  Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[14]  T. Ebner,et al.  Disposition and chemical stability of telmisartan 1-O-acylglucuronide. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[15]  R. Grunert,et al.  THE IN VIVO ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). I. PROPHYLACTIC AND THERAPEUTIC ACTIVITY AGAINST INFLUENZA VIRUSES. , 1965, Virology.

[16]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[17]  M. Griffin.  Influenza vaccination: a 21st century dilemma. , 2013, South Dakota medicine : the journal of the South Dakota State Medical Association.

[18]  S. Rathore,et al.  Synthesis, Isolation and Characterization of Process-Related Impurities in Oseltamivir Phosphate , 2012 .

[19]  S. Kailasam.  Rapid method development to study plasma stability of diverse pharmaceutical compounds using Rapid Resolution LC and triple quadrupole MS , 2009 .

[20]  T. Foderaro,et al.  Research and Development of a Second-Generation Process for Oseltamivir Phosphate, Prodrug for a Neuraminidase Inhibitor , 2004 .

[21]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..